The cardioprotective effects of the thromboxane receptor antagonist SQ 30,741 are not reversed by aspirin
- 1 March 1991
- journal article
- Published by Springer Nature in Basic Research in Cardiology
- Vol. 86 (2) , 99-106
- https://doi.org/10.1007/bf02190542
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- The Effect of the Thromboxane A2/Prostaglandin Endoperoxide Receptor Antagonist SQ 30,741 on Myocardial Infarct Size and Blood Flow During Myocardial Ischemia and ReperfusionJournal of Cardiovascular Pharmacology, 1988
- Lack of involvement of thromboxane A2 in postischemic recovery of stunned canine myocardium.Circulation, 1988
- Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism.Circulation Research, 1988
- Effect of the Thromboxane Receptor Antagonist SQ 29,548 on Myocardial Infarct Size in DogsJournal of Cardiovascular Pharmacology, 1988
- Myocardial ischemia: platelet and thromboxane concentrations in cardiac lymph and the effects of ibuprofen and prostacyclin.Circulation Research, 1986
- Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemiaEuropean Journal of Pharmacology, 1986
- Platelet Depletion and Infarct Size in an Occlusion Reperfusion Model of Myocardial Ischemia in Anesthetized DogsJournal of Cardiovascular Pharmacology, 1985
- Platelet depletion in experimental myocardial infarctionBasic Research in Cardiology, 1985
- Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmiasNature, 1981
- Influence of thromboxane inhibition on the severity of myocardial ischemia in catsCanadian Journal of Physiology and Pharmacology, 1980